Editas Medicine, Inc. (EDIT) CEO Sells $204,200.00 in Stock
Editas Medicine, Inc. (NASDAQ:EDIT) CEO Katrine Bosley sold 10,000 shares of Editas Medicine stock in a transaction that occurred on Friday, September 1st. The stock was sold at an average price of $20.42, for a total value of $204,200.00. Following the transaction, the chief executive officer now owns 1,414,629 shares of the company’s stock, valued at $28,886,724.18. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink.
Katrine Bosley also recently made the following trade(s):
- On Tuesday, September 5th, Katrine Bosley sold 16,666 shares of Editas Medicine stock. The stock was sold at an average price of $20.33, for a total value of $338,819.78.
- On Friday, August 11th, Katrine Bosley sold 16,666 shares of Editas Medicine stock. The stock was sold at an average price of $20.02, for a total value of $333,653.32.
Editas Medicine, Inc. (NASDAQ:EDIT) opened at 20.09 on Friday. Editas Medicine, Inc. has a one year low of $12.43 and a one year high of $29.20. The firm’s market capitalization is $822.20 million. The firm has a 50-day moving average price of $18.77 and a 200 day moving average price of $19.11.
Editas Medicine (NASDAQ:EDIT) last issued its earnings results on Wednesday, August 9th. The company reported ($0.65) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.64) by $0.01. The business had revenue of $3.10 million for the quarter, compared to the consensus estimate of $2.20 million. Editas Medicine had a negative return on equity of 67.75% and a negative net margin of 2,091.36%. The company’s quarterly revenue was down 8.8% on a year-over-year basis. During the same quarter in the previous year, the business posted ($0.54) earnings per share. Equities research analysts anticipate that Editas Medicine, Inc. will post ($2.88) earnings per share for the current year.
COPYRIGHT VIOLATION NOTICE: “Editas Medicine, Inc. (EDIT) CEO Sells $204,200.00 in Stock” was first posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this piece of content on another site, it was stolen and republished in violation of international copyright and trademark law. The legal version of this piece of content can be accessed at https://www.thecerbatgem.com/2017/09/09/editas-medicine-inc-edit-ceo-sells-204200-00-in-stock.html.
A number of large investors have recently modified their holdings of EDIT. IHT Wealth Management LLC bought a new stake in Editas Medicine during the second quarter worth approximately $107,000. DekaBank Deutsche Girozentrale acquired a new position in Editas Medicine in the 2nd quarter worth approximately $127,000. Bank of America Corp DE boosted its stake in Editas Medicine by 72.2% in the 1st quarter. Bank of America Corp DE now owns 5,936 shares of the company’s stock worth $133,000 after purchasing an additional 2,489 shares during the period. Legal & General Group Plc boosted its stake in Editas Medicine by 308.4% in the 2nd quarter. Legal & General Group Plc now owns 8,654 shares of the company’s stock worth $145,000 after purchasing an additional 6,535 shares during the period. Finally, Creative Planning boosted its stake in Editas Medicine by 8,910.9% in the 2nd quarter. Creative Planning now owns 9,101 shares of the company’s stock worth $153,000 after purchasing an additional 9,000 shares during the period. Hedge funds and other institutional investors own 70.17% of the company’s stock.
Several research analysts recently issued reports on EDIT shares. Zacks Investment Research downgraded Editas Medicine from a “buy” rating to a “hold” rating in a research report on Tuesday, July 18th. Cann started coverage on Editas Medicine in a research report on Monday, July 17th. They set a “market perform” rating for the company. J P Morgan Chase & Co set a $27.00 price objective on Editas Medicine and gave the stock a “hold” rating in a research report on Wednesday, August 9th. Barclays PLC started coverage on Editas Medicine in a research report on Wednesday. They set an “overweight” rating and a $28.00 price objective for the company. Finally, Oppenheimer Holdings, Inc. reiterated a “market perform” rating on shares of Editas Medicine in a research report on Tuesday, July 18th. Five equities research analysts have rated the stock with a hold rating, four have issued a buy rating and one has given a strong buy rating to the stock. Editas Medicine presently has a consensus rating of “Buy” and an average target price of $25.52.
Editas Medicine Company Profile
Editas Medicine, Inc is a genome editing company. It is engaged in treating patients with genetically defined diseases by correcting their disease-causing genes. It operates through developing and commercializing genome editing technology segment. It is developing a genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR) technology.
Receive News & Stock Ratings for Editas Medicine Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Editas Medicine Inc. and related stocks with our FREE daily email newsletter.